Skip to main content

Canada approves new obesity drug to reduce risk of non-fatal heart attack

A dosage of Wegovy is seen in Front Royal, Va., on Friday, March 1, 2024. (AP Photo/Amanda Andrade-Rhoades) A dosage of Wegovy is seen in Front Royal, Va., on Friday, March 1, 2024. (AP Photo/Amanda Andrade-Rhoades)
Share

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or myocardial infarction in some adults, the Danish drugmaker said on Wednesday.

Wegovy has become the first approved treatment in Canada to address both obesity and the risk of heart-related conditions in adults with established cardiovascular disease, according to Novo.

The European Union health regulator recently backed the drug for reducing the risk of major cardiovascular events and strokes in overweight or obese adults without diabetes.

Wegovy is also approved in the U.K. and the U.S. to lower the risk of serious heart problems or strokes in overweight and obese adults.

The drug, chemically known as semaglutide, has been authorized in Canada to treat obesity since 2021.

(Reporting by Mariam Sunny in Bengaluru; Editing by Tasim Zahid)

CTVNews.ca Top Stories

BREAKING

BREAKING Liberals table GST holiday legislation, putting $250 rebate on backburner

Prime Minister Justin Trudeau's promised holiday consumer relief package has been split in half. After NDP Leader Jagmeet Singh said his party was only ready to help pass the GST/HST holiday portion of the affordability announcement, Deputy Prime Minister and Finance Minister Chrystia Freeland tabled legislation Wednesday that only seeks to enact that measure.

Local Spotlight

100-year-old Winnipeg man walks blocks to see his wife

It's considered lucky to live to be 100, but often when you hit that milestone, you're faced with significant mobility issues. Not Winnipeg's Jack Mudry. The centenarian regularly walks five blocks to get where he wants to go, the care home where his wife Stella lives.

Stay Connected